M. Link, A. Goorin, M. Horowitz, W. Meyer, J. Belasco et al., Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the Multi-Institutional Osteosarcoma Study, Clin Orthop Relat Res, issue.270, pp.8-14, 1991.

G. Rosen, M. Murphy, A. Huvos, G. Mmarcove, and R. , Chemotherapy,en bloc resection, and prosthetic bone replacement in the treatment of osteogenic sarcoma, Cancer, vol.32, issue.1, pp.1-11, 1976.
DOI : 10.1002/1097-0142(197601)37:1<1::AID-CNCR2820370102>3.0.CO;2-3

A. Provisor, L. Ettinger, J. Nachman, M. Krailo, J. Makley et al., Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group., Journal of Clinical Oncology, vol.15, issue.1, pp.76-84, 1997.
DOI : 10.1200/JCO.1997.15.1.76

D. Heymann, B. Ory, F. Gouin, G. Jrredini, and F. , Bisphosphonates: new therapeutic agents for the treatment of bone tumors, Trends in Molecular Medicine, vol.10, issue.7, pp.337-380, 2004.
DOI : 10.1016/j.molmed.2004.05.007

M. Rogers, S. Gordon, H. Benford, F. Coxon, S. Luckman et al., Cellular and molecular mechanisms of action of bisphosphonates, Cancer, vol.20, issue.52, pp.2961-78, 2000.
DOI : 10.1002/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L

M. Rogers, New Insights Into the Molecular Mechanisms of Action of Bisphosphonates, Current Pharmaceutical Design, vol.9, issue.32, pp.2643-58, 2003.
DOI : 10.2174/1381612033453640

R. Russell, Bisphosphonates: Mode of Action and Pharmacology, PEDIATRICS, vol.119, issue.Supplement, pp.150-62, 2007.
DOI : 10.1542/peds.2006-2023H

F. Coxon, M. Helfrich, R. Van-'t-hof, S. Sebti, S. Ralston et al., Protein Geranylgeranylation Is Required for Osteoclast Formation, Function, and Survival: Inhibition by Bisphosphonates and GGTI-298, Journal of Bone and Mineral Research, vol.108, issue.8, pp.1467-76, 2000.
DOI : 10.1359/jbmr.2000.15.8.1467

P. Mackie, J. Fisher, Z. Hchoong, and P. , Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line, British Journal of Cancer, vol.84, issue.7, pp.951-959, 2001.
DOI : 10.1054/bjoc.2000.1679

J. Sonnemann, V. Eckervogt, B. Truckenbrod, J. Boos, W. Wvan-valen et al., The bisphosphonate pamidronate is a potent inhibitor of human osteosarcoma cell growth in vitro, Anti-Cancer Drugs, vol.12, issue.5, pp.459-65, 2001.
DOI : 10.1097/00001813-200106000-00007

D. Heymann, B. Ory, F. Blanchard, M. Heymann, P. Coipeau et al., Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma, Bone, vol.37, issue.1, pp.74-86, 2005.
DOI : 10.1016/j.bone.2005.02.020

B. Ory, M. Heymann, A. Kamijo, F. Gouin, H. Dredini et al., Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice, Cancer, vol.91, issue.11, pp.2522-2531, 2005.
DOI : 10.1002/cncr.21530

B. Ory, F. Blanchard, S. Battaglia, F. Gouin, R. Fheymann et al., Zoledronic Acid Activates the DNA S-Phase Checkpoint and Induces Osteosarcoma Cell Death Characterized by Apoptosis-Inducing Factor and Endonuclease-G Translocation Independently of p53 and Retinoblastoma Status, Molecular Pharmacology, vol.71, issue.1, pp.333-376, 2007.
DOI : 10.1124/mol.106.028837

M. Gottesman, Mechanisms of Cancer Drug Resistance, Annual Review of Medicine, vol.53, issue.1, pp.615-642, 2002.
DOI : 10.1146/annurev.med.53.082901.103929

M. Gottesman, S. Ambudkar, B. Ni, J. Aran, and Y. Sugimoto, Exploiting Multidrug Resistance to Treat Cancer, Cold Spring Harbor Symposia on Quantitative Biology, vol.59, issue.0, pp.677-83, 1994.
DOI : 10.1101/SQB.1994.059.01.078

T. Ozben, Mechanisms and strategies to overcome multiple drug resistance in cancer, FEBS Letters, vol.52, issue.12, pp.2903-2912, 2006.
DOI : 10.1016/j.febslet.2006.02.020

C. Jasmin, M. Allouche, J. Jude, B. Klein, J. Thiery et al., An experimental model of osteosarcomas in rats ], Sem Hop, vol.58, pp.28-29, 1982.

B. Klein, S. Pals, R. Masse, J. Lafuma, M. Morin et al., Studies of bone and soft-tissue tumours induced in rats with radioactive cerium chloride, International Journal of Cancer, vol.3, issue.1, pp.112-121, 1977.
DOI : 10.1002/ijc.2910200118

B. Jlriehm and H. , Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies, Cancer Res, vol.30, issue.4, pp.1174-84, 1970.

G. Mmpastan and I. , Biochemistry of multidrug resistance mediated by the multidrug transporter, Annu Rev Biochem, vol.62, pp.385-427, 1993.

T. Tsuruo, H. Iida, T. Ssakurai, and Y. , Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil, Cancer Res, vol.41, issue.5, pp.1967-72, 1981.

G. Jboliff and A. , The potential of farnesyltransferase inhibitors as cancer chemotherapeutics, Annu Rev Pharmacol Toxicol, vol.37, pp.143-66, 1997.

S. Suri, J. Monkkonen, M. Taskinen, J. Pesonen, M. Blank et al., Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: a model of bisphosphonate-induced gastrointestinal toxicity, Bone, vol.29, issue.4, pp.336-379, 2001.
DOI : 10.1016/S8756-3282(01)00589-0

A. Reszka, H. Jrodan, and G. , Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation, Mol Pharmacol, vol.59, issue.2, pp.193-202, 2001.

G. Kruh, Introduction to resistance to anticancer agents, Oncogene, vol.22, issue.47, pp.7262-7266, 2003.
DOI : 10.1038/sj.onc.1206932

F. Coxon, T. Krogers, and M. , Recent advances in understanding the mechanism of action of bisphosphonates, Current Opinion in Pharmacology, vol.6, issue.3, pp.307-319, 2006.
DOI : 10.1016/j.coph.2006.03.005

M. Notarnicola, C. Messa, A. Cavallini, M. Bifulco, M. Tecce et al., Higher Farnesyl Diphosphate Synthase Activity in Human Colorectal Cancer Inhibition of Cellular Apoptosis, Oncology, vol.67, issue.5-6, pp.5-6, 2004.
DOI : 10.1159/000082918

A. Ortiz-gomez, C. Jimenez, A. Estevez, J. Carrero-lerida, D. Ruiz-perez-lmgonzalez-pacanowska et al., Farnesyl diphosphate synthase is a cytosolic enzyme in Leishmania major promastigotes and its overexpression confers resistance to risedronate Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates, Eukaryot Cell. Bone, vol.5, issue.335, pp.805-816, 2003.

M. Salomo, J. Jurlander, N. Lbgimsing, and P. , How myeloma cells escape bisphosphonate-mediated killing: development of specific resistance with preserved sensitivity to conventional chemotherapeutics, British Journal of Haematology, vol.13, issue.2, pp.202-212, 2003.
DOI : 10.1046/j.1365-2141.2002.03257.x

I. Ifergan, I. Meller, I. Jassaraf, and Y. , Reduced folate carrier protein expression in osteosarcoma, Cancer, vol.13, issue.9, pp.1958-66, 2003.
DOI : 10.1002/cncr.11741

H. Zhou, R. Randall, A. Brothman, T. Maxwell, C. Cmgoldsby et al., HER-2/ neu Expression in Osteosarcoma Increases Risk of Lung Metastasis and Can Be Associated With Gene Amplification, Journal of Pediatric Hematology/Oncology, vol.25, issue.1, pp.27-32, 2003.
DOI : 10.1097/00043426-200301000-00007

A. Endo, The discovery and development of HMG-CoA reductase inhibitors, Atherosclerosis Supplements, vol.5, issue.3, pp.1569-82, 1992.
DOI : 10.1016/j.atherosclerosissup.2004.08.026

S. Doggrell, Statins in the 21st century: end of the simple story?, Expert Opinion on Investigational Drugs, vol.84, issue.69, pp.1755-66, 2001.
DOI : 10.1016/S0002-9149(99)00132-0

C. Ajgorlick and R. , Chemotherapy resistance in osteosarcoma: current challenges and future directions, Expert Rev Anticancer Ther, vol.6, issue.7, pp.1075-85, 2006.

A. Cacrist and W. , Common musculoskeletal tumors of childhood and adolescence, N Engl J Med, vol.341, issue.5, pp.342-52, 1999.

J. Sandberg-aabridge, Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: osteosarcoma and related tumors, Cancer Genetics and Cytogenetics, vol.145, issue.1, pp.1-30, 2003.
DOI : 10.1016/S0165-4608(03)00105-5

M. Benassi, L. Molendini, G. Gamberi, P. Ragazzini, M. Sollazzo et al., Alteration of pRb/p16/cdk4 regulation in human osteosarcoma, International Journal of Cancer, vol.7, issue.5, pp.489-93, 1999.
DOI : 10.1002/(SICI)1097-0215(19991022)84:5<489::AID-IJC7>3.0.CO;2-D

J. David, D. Mehic, L. Bakiri, A. Schilling, V. Mandic et al., Essential role of RSK2 in c-Fos???dependent osteosarcoma development, Journal of Clinical Investigation, vol.115, issue.3, pp.664-72, 2005.
DOI : 10.1172/JCI22877DS1

G. Wei, F. Lonardo, T. Ueda, T. Kim, A. Huvos et al., CDK4 gene amplification in osteosarcoma: Reciprocal relationship withINK4A gene alterations and mapping of 12q13 amplicons, International Journal of Cancer, vol.54, issue.2, pp.199-204, 1999.
DOI : 10.1002/(SICI)1097-0215(19990118)80:2<199::AID-IJC7>3.0.CO;2-4

J. Grem, S. King, W. Releyland-jones, and B. , The Role of Methotrexate in Osteosarcoma, JNCI Journal of the National Cancer Institute, vol.80, issue.9, pp.626-55, 1988.
DOI : 10.1093/jnci/80.9.626

Z. Siddik, Cisplatin: mode of cytotoxic action and molecular basis of resistance, Oncogene, vol.22, issue.47, pp.7265-79, 2003.
DOI : 10.1038/sj.onc.1206933

G. Beretta, L. Gatti, S. Tinelli, E. Corna, D. Colangelo et al., Cellular pharmacology of cisplatin in relation to the expression of human copper transporter CTR1 in different pairs of cisplatin-sensitive and -resistant cells, Biochemical Pharmacology, vol.68, issue.2, pp.283-91, 2004.
DOI : 10.1016/j.bcp.2004.03.022

M. Serra, M. Pasello, M. Manara, K. Scotlandi, S. Ferrari et al., May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol, International Journal of Oncology, vol.29, issue.6, pp.1459-68, 2006.
DOI : 10.3892/ijo.29.6.1459